Wall Street Analyst Downgrade VistaGen Therapeutics Inc. [VTGN]. What else is Wall St. saying


VistaGen Therapeutics Inc. [NASDAQ: VTGN] It fell by -$0.01 during the normal trading session on Wednesday and reached a high of $0.1745 on the day while closing the day at $0.16. Company report on September 20 2022 To have Sean Singh, CEO of Vistagen, join the executive roundtable to discuss mental health at the annual Concordia Summit.

Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now .

sponsored by

Goldie Hawn leads the discussion on mental health support around the world with CEOs, politicians, nonprofit leaders and entrepreneurs about the importance of mental health.

Vistagen (Nasdaq: VTGN), a late-stage clinical biopharmaceutical company that aims to change the treatment landscape for individuals with anxiety, depression, and other central nervous system (CNS) disorders, announced today that its CEO, Sean Singh, will participate in a roundtable Executive Special on September 20 at the annual Concordia Summit 2022 taking place September 19-21, 2022 in New York City.

VistaGen Therapeutics Inc stock also lost ground. -13.83% of its value over the past seven days. However, VTGN stock is down -83.99% in the three months of the year. Over the past six months, it has lost -85.92% and lost -91.63% year on year.

The market capitalization of VTGN shares was $33.94 million, with 206.60 million shares outstanding and 205.00 million shares in the current float. Compared to an average trading volume of 14.82 million shares, VTGN’s trading volume was 5110619 on the last trading day, which is why market watchers consider the stock to be active.

Here’s what leading stock market experts are saying about VistaGen Therapeutics Inc. [VTGN]:

William Blair made an appreciation for the stock of VistaGen Therapeutics Inc. , retaining their opinion on the stock as Mkt Perform, with their previous recommendation back on July 22, 2022. The new note on price target was issued on July 22, 2022, which is the official target price for VistaGen Therapeutics Inc. stock.

The Average True Range (ATR) was set by VistaGen Therapeutics Inc. at 0.02, with the price-to-sales ratio for VTGN stock in the last 12-month period standing at 30.86. The price-to-book ratio for the last quarter was 0.74, with the price-to-cash ratio for the stock in the same quarter set at 0.25.

VTGN stock trading performance evaluation

VistaGen Therapeutics Inc. [VTGN] It fell into the red at the end of last week, fell in a negative direction and fell by -13.83. With this latest performance, VTGN shares are down -12.20% over the past four-week period, as well as -85.92% over the past six months – not to mention a -94.15% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for VTGN stock for the last two weeks was set at 35.84, with the RSI for the last one traded at 34.28, and the three-week RSI for VistaGen Therapeutics Inc. [VTGN]. The current moving average of the last 50 trading days for this stock is 0.2742 while it recorded at 0.1799 for the last trading week, and 1.0945 for the last 200 days.

VistaGen Therapeutics Inc. [VTGN]: Insight into the basic fundamentals

Operating margin for any stock indicates how profitable the investment is, VistaGen Therapeutics Inc. [VTGN] The stock currently has operating margin of -4308.68 and gross margin of +26.49. Net margin reported to VistaGen Therapeutics Inc. Currently at -4307.19.

The return on equity for this stock fell to -60.96, with the return on assets remaining at -52.22.

The liquidity data of VistaGen Therapeutics Inc. Interesting too, with a quick ratio of 6.20 and a current ratio of 6.20.

VistaGen Therapeutics Inc. [VTGN]: Insiders ownership positions

There is currently about $23 million, or 71.40% of VTGN’s equity, in the hands of institutional investors. The three largest institutional owners of VTGN shares are: VR ADVISER, LLC with 20,697,286 ownership, which is approximately 28.977% of the company’s market capitalization and approximately 0.30% of the total institutional ownership; NEA MANAGEMENT COMPANY, LLC, which owns 16,302,596 shares with an approximate value of $2.66 million in VTGN stock; and ORBIMED ADVISORS LLC, currently worth $2.19 million in VTGN stock with ownership of approximately 3.966% of the company’s market capitalization.

Positions increased in shares of VistaGen Therapeutics Inc. held by institutional investors at the end of August and at the time of the August report, as 54 institutional owners consolidated their position in VistaGen Therapeutics Inc. [NASDAQ:VTGN] About 15551886 shares. In addition, the number of investors’ positions decreased by 59 investors by about 10.780687 shares, while 21 investors occupied positions by about 112.435.075 shares. The said changes put institutional holdings at 138,767,648 shares, according to the latest report from the Securities and Exchange Commission. VTGN’s stock included 21 new institutional investments with a total of 5,364,747 shares, while 22 institutional investors sold positions of 5,185,656 shares during the same period.

Leave A Reply

Your email address will not be published.